Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039817 · ClinicalTrials.gov registry record · Phase 1
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
A Phase 1 study, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02039817 is a Phase 1 study that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT02039817, a Phase 1 study, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers with normal renal function.
Interventions
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039817
The ClinicalTrials.gov registry entry for NCT02039817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IDN-6556 is the first listed.
NCT02039817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039817 about?
NCT02039817 is a clinical study titled "PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers". This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers with normal renal function.
What is the current status of trial NCT02039817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02039817?
The interventions under investigation include: IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT02039817?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.